Regulatory filing 📈 Stocks 🌍 United States

Adagio Medical Reports Q3 Results Amid Strategic Review and Reverse Split

Adagio Medical faces financial strain with $3.1 million in cash and paused European operations, prompting a board-led strategic review as it navigates FDA review for its vCLAS system and recent reverse stock split.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ADGM → 5/10 (50% confidence).

📊 Affected Assets (1)

ADGM
Neutral 🤖 50%
📅 Short-term 🌍 US · Explicit

Q3 net income of $17.8 million ($2.40 basic EPS) is entirely driven by a $23.0 million noncash fair-value gain on its 13% Convertible Notes, masking a diluted loss of $(5.13) per share. Cash of only $3.1 million, a pause in European commercial activity, a 1-for-30 reverse split to regain Nasdaq bid-price compliance, and a Board-initiated strategic alternatives review point to financial strain, but the strategic review could unlock value for shareholders. Good and bad largely cancel out.

Catalysts
  • • Board-initiated formal process to explore strategic alternatives to maximize shareholder value
  • • PMA application for the vCLAS Ventricular Ablation System still under FDA review
Risk Factors
  • • Cash and cash equivalents of only $3.1 million as of September 30, 2026
  • • Commercial activity in Europe paused, with zero revenue in the quarter

🎯 Key Takeaways

  • Reported Q3 2026 net income of $17.8 million, masking a diluted net loss per share of $(5.13).
  • Cash and cash equivalents totaled $3.1 million as of September 30, 2026.
  • Board of Directors initiated a formal process to explore strategic alternatives to maximize shareholder value.
  • Effected a 1-for-30 reverse stock split on November 6, 2026, to regain Nasdaq minimum bid price compliance.
  • Revenue for the third quarter was nil due to a pause in European commercial activity.

📝 Executive Summary

Adagio Medical Holdings reported Q3 2026 net income of $17.8 million, driven by a $23.0 million noncash gain on convertible notes, while facing a diluted loss of $(5.13) per share. The company, which holds $3.1 million in cash, has initiated a formal process to explore strategic alternatives and recently completed a 1-for-30 reverse stock split to regain Nasdaq compliance.

❓ FAQ

Did Adagio actually make a profit this quarter?

Reported net income was $17.8 million ($2.40 per basic share), but it came from a $23.0 million noncash gain related to its 13% Senior Secured Convertible Notes; on a diluted basis the company still reported a loss of $5.13 per share.

What does the strategic alternatives review mean for the stock?

The Board has started a formal process focused on maximizing shareholder value, which could lead to a sale or other transaction, but the article does not specify any terms or outcome.